Veloxis Pharmaceuticals
secondary
spacer
Corporate Profile##outline
A US pharmaceutical company, Veloxis sells an immunosuppressive drug using proprietary drug delivery technology* to help prevent organ rejection after kidney transplants. Veloxis is enhancing licensing activity to obtain new pharmaceuticals as growth drivers to accelerate the Asahi Kasei Group’s transformation to a global healthcare enterprise.
- Technology to enhance the effects and/or reduce the side effects of drugs by controlling their absorption, distribution, metabolism, and excretion
1
spacer
column-header
Trade name
Veloxis Pharmaceuticals, Inc.
https://www.veloxis.com/
https://www.veloxis.com/
Main businesses
Research, development, manufacture, and sale of pharmaceuticals for organ transplantation
Home office
2000 Regency Parkway, Suite 500, Cary, NC 27518, USA
President
Stacy G. Wheeler
Paid-in capital
US$1,117 million (including capital surplus)
Shareholder
Asahi Kasei Corp.
Phone
+1-919-591-3090
(as of October 1, 2024)
Officers##officer
column-header
Stacy G. Wheeler
Chief Executive Officer, Board Director
Yoshikazu Aoki
Board Director
Ken Shinomiya
Board Director
Fredrik Johansson
Executive Officer
Chief Financial Officer
Chief Financial Officer
Carl Kraus
Executive Officer
Chief Medical Officer
Chief Medical Officer
Ed Sleeper
Executive Officer
Chief Ethics and Compliance Officer
Chief Ethics and Compliance Officer
V. Noel Barnard
Executive Officer
Vice President, Legal and General Counsel; Secretary
Vice President, Legal and General Counsel; Secretary
Neil Morton
Executive Officer
Vice President, Global Business Development
Vice President, Global Business Development
(as of April 1, 2026)
column-header
column-header
column-header
column-header
column-header